

Trastuzumab emtansine (T-DM1) KATHERINE

### PRELIMINARY SCORE

#### CURATIVE



Scoring of iDFS on the same basis as DFS

#### NON-CURATIVE



### ADJUSTMENTS

#### Quality of life



QoL data pending



#### Serious and disabling adverse effects



#### Other adjustments



Trastuzumab emtansine (T-DM1) KATHERINE

### SCORE

#### CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

#### NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

#### INFORMATION

Therapeutic Indication: Adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease in the breast and/or lymph nodes after neoadjuvant taxane-based and HER2-targeted therapy  
 Experimental Arm: Trastuzumab emtansine (T-DM1)  
 Control Arm: Trastuzumab

